Projects
Molecular and functional imaging as a pivotal tool for translational medicine in the field of neuroscience and oncology: a platform creating a bridge between basic research, clinical development and industrial application. KU Leuven
Development of an image-based multiparametric drug response signature to predict clinical therapy response in cancer patients from ex vivo tumoroid screenings. University of Antwerp
Clinical applications of computational cytometry Ghent University
Flow cytometry is an essential technique in the fields of immunology and oncology, allowing insights at the individual cell level at relatively low cost, complementary to genetics and other clinical parameters. Due to recent technological advancements, this field is moving towards more automated analysis approaches. In this research proposal, I will work on two methods to aid researchers using flow cytometry. First, I will develop an ...
Accellerating towards clinical validation of Galsome nanovaccines Ghent University
Although the Galsome mRNA vaccine platform has a broad application potential, we opt to first accelerate validation and valorization of Galsomes for treatment of solid tumors. The first objective is to accelerate the translation of Galsomes to a clinical-grade product. This in view of a phase Ia/b clinical trial in lung cancer patients. FThe second objective aims to address the market trend for targeting “neo-antigens” by validating ...
BOF ZAP clinical pharmacology Ghent University
A professorship granted by the Special Research Fund is a primarily research-oriented position and is made available for excellent researchers with a high-quality research programme.
Clinical sabbatical Koen Van Laere: Nuclear imaging. KU Leuven
The purpose of this clinical sabbatical is to further deepen and study our nuclear imaging topics.
Towards clinical testing of improved, less toxic and less immunogenic, L-asparaginase preparations for the treatment of acute lymphoblastic leukemia Ghent University
L-asparaginase (L-ASNase) is a pivotal enzymatic drug in the treatment of acute lymphoblastic leukemia (ALL). Unfortunately, in ~15% of L-ASNase treated patients, immune reactions are observed that result in loss of enzyme and thus anti-cancer activity. In addition, these bacterial L-ASNases harbor L-glutaminase (L-GLNase) co-activity, which is responsible for most of the observed adverse toxicities, including hepatoxicity and pancreatitis. ...